Barclays Issues Pessimistic Forecast for Aspen Aerogels (NYSE:ASPN) Stock Price

Aspen Aerogels (NYSE:ASPN) had its target price decreased by stock analysts at Barclays from $4.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “underweight” rating on the construction company’s stock. Barclays‘s price objective points to a potential downside of 9.09% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Zacks Research upgraded Aspen Aerogels from a “strong sell” rating to a “hold” rating in a report on Thursday, January 15th. TD Cowen lowered their price objective on shares of Aspen Aerogels from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Roth Mkm cut their target price on shares of Aspen Aerogels from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Canaccord Genuity Group reduced their price target on shares of Aspen Aerogels from $10.00 to $5.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aspen Aerogels in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Aspen Aerogels currently has a consensus rating of “Hold” and a consensus price target of $4.25.

Aspen Aerogels Trading Down 1.5%

Shares of ASPN traded down $0.05 during trading hours on Thursday, reaching $3.30. 577,555 shares of the company traded hands, compared to its average volume of 1,647,722. The stock’s fifty day moving average price is $3.35 and its 200 day moving average price is $4.95. The company has a current ratio of 3.94, a quick ratio of 3.33 and a debt-to-equity ratio of 0.28. The firm has a market cap of $272.74 million, a price-to-earnings ratio of -0.70 and a beta of 2.99. Aspen Aerogels has a 12-month low of $2.30 and a 12-month high of $9.78.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Wednesday, February 25th. The construction company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The company had revenue of $41.34 million during the quarter, compared to analysts’ expectations of $44.25 million. Aspen Aerogels had a negative net margin of 143.69% and a negative return on equity of 13.07%. Aspen Aerogels’s quarterly revenue was down 66.4% on a year-over-year basis. During the same period last year, the firm earned $0.14 earnings per share. Aspen Aerogels has set its Q1 2026 guidance at -0.280–0.240 EPS. Sell-side analysts forecast that Aspen Aerogels will post 0.17 earnings per share for the current year.

Institutional Investors Weigh In On Aspen Aerogels

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Aspen Aerogels by 237.9% in the 4th quarter. Invesco Ltd. now owns 4,129,934 shares of the construction company’s stock valued at $11,688,000 after buying an additional 2,907,558 shares during the period. Federated Hermes Inc. purchased a new stake in Aspen Aerogels in the 2nd quarter worth approximately $10,459,000. Needham Investment Management LLC boosted its position in Aspen Aerogels by 26.5% in the 4th quarter. Needham Investment Management LLC now owns 4,351,700 shares of the construction company’s stock worth $12,315,000 after purchasing an additional 912,000 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Aspen Aerogels by 105.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,246,506 shares of the construction company’s stock worth $7,379,000 after purchasing an additional 639,753 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Aspen Aerogels by 89.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company’s stock valued at $8,143,000 after purchasing an additional 602,586 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Aspen Aerogels

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.